Camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in untreated extensive-stage small-cell lung cancer: a nonrandomized clinical trial

Camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in untreated extensive-stage small-cell lung cancer: a nonrandomized clinical trial

BackgroundProgrammed cell death-ligand 1 (PD-L1) inhibitors plus chemotherapy have made substantial progress in extensive-stage small-cell lung cancer (ES-SCLC), but the survival benefit is still limited. This study aimed to evaluate the preliminary efficacy and safety of camrelizumab plus platinum-...

Full description

Bibliographic Details
Main Authors: Jun Ni, Xiaoyan Si, Hanping Wang, Xiaotong Zhang, Li Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-04-01
Series:Frontiers in Immunology
Subjects:
small cell lung carcinoma (SCLC)
platinum
irinotecan
camrelizumab
immune checkpoint inhibitors
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1168879/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1168879/full

Similar Items